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Shigella spp. are food- and waterborne pathogens that cause severe diarrheal and dysenteric disease associated with high mor-
bidity and mortality. Individuals most often affected are children under 5 years of age in the developing world. The existence of
multiple Shigella serotypes and the heterogenic distribution of pathogenic strains, as well as emerging antibiotic resistance, re-
quire the development of a broadly protective vaccine. All Shigella spp. utilize a type III secretion system (TTSS) to initiate infec-
tion. The type III secretion apparatus (TTSA) is the molecular needle and syringe that form the energized conduit between the
bacterial cytoplasm and the host cell to transport effector proteins that manipulate cellular processes to benefit the pathogen.
IpaB and IpaD form a tip complex atop the TTSA needle and are required for pathogenesis. Because they are common to all viru-
lent Shigella spp., they are ideal candidate antigens for a subunit-based, broad-spectrum vaccine. We examined the immunoge-
nicity and protective efficacy of IpaB and IpaD, alone or combined, coadministered with a double mutant heat-labile toxin
(dmLT) from Escherichia coli, used as a mucosal adjuvant, in a mouse model of intranasal immunization and pulmonary chal-
lenge. Robust systemic and mucosal antibody- and T cell-mediated immunities were induced against both proteins, particularly
IpaB. Mice immunized in the presence of dmLT with IpaB alone or IpaB combined with IpaD were fully protected against lethal
pulmonary infection with Shigella flexneri and Shigella sonnei. We provide the first demonstration that the Shigella TTSAs IpaB
and IpaD are promising antigens for the development of a cross-protective Shigella vaccine.
Shigellosis is a severe diarrheal disease associated with highmorbidity and mortality rates, particularly in the developing
world. It is also responsible for long-term effects on cognitive and
physical development in children (51). The global burden has
been estimated at more than 160 million cases per year, with the
most affected being children under 5 years of age living in areas of
Shigella endemicity (24). The organism can be transmitted from
person to person through fecal-oral contact or through contami-
nated fomites; ingestion of as few as 10 organisms can cause illness
in adult volunteers (11). In industrialized countries, Shigella is
known to be responsible for cases of pediatric diarrhea and to
cause occasional food-borne outbreaks (6). Other susceptible
groups include travelers, military personnel, and refugees (53).
Additionally, the Centers for Disease Control and Prevention lists
Shigella as a category B bioterrorist agent (food safety threat).
The Shigella genus comprises four different species: Shigella
dysenteriae, Shigella flexneri, Shigella sonnei, and Shigella boydii.
These organisms are further divided into multiple serotypes based
on the structure of the O polysaccharide portion of their outer
membrane lipopolysaccharide (LPS), thereby increasing their an-
tigenic variability. One serotype in particular, S. dysenteriae sero-
type 1, which produces Shiga toxin, is responsible for the most
severe infections, including hemolytic uremic syndrome (15), and
it is the cause of epidemic dysentery. Additionally, serotypes can
drift during outbreaks, further limiting the efficacy of vaccines
that are restricted to particular serotypes (37, 56). The emergence
of strains resistant to antimicrobial drugs, including ciprofloxa-
cin, currently the first-line antibiotic treatment against Shigella
infections (20, 46, 55), heightens the difficulty of controlling this
pathogen and makes the development of an effective vaccine even
more urgent.
Despite being a longstanding priority for the World Health
Organization (54) and despite the progress made in recent years
(27), no licensed vaccine for Shigella spp. currently exists. Efforts
to develop a vaccine against this pathogen have included the use of
killed bacteria (31), live attenuated (1, 19, 22, 38) and recombi-
nant carrier (21) organisms, polysaccharide conjugates (7, 36),
and LPS-protein mixtures (16, 48). When tested in humans, these
vaccines were either too reactogenic or poorly immunogenic. A
major disadvantage of these candidates is the O antigen restric-
tion, which limits the scope of protection they can offer and re-
quires the development of a multiserotype vaccine to provide ad-
equate protective coverage in areas of Shigella endemicity.
The type III secretion system (TTSS) is a common virulence
mechanism in many Gram-negative pathogens. The TTSS appa-
ratus (TTSA) resembles a molecular needle and syringe and is
present at a density of 50 to 100 per bacterial cell (4). It provides an
energized conduit for the translocation of effector proteins from
the bacterial cytoplasm to the host cell cytoplasm for the benefit of
the pathogen. The Shigella TTSA needle tip protein is IpaD, which
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resides atop the TTSA needle in a pentameric ring where it con-
trols translocator and effector protein secretion (14). The crystal
structure of IpaD (37 kDa) reveals a dumbbell-like structure, with
the handle being a coiled coil that is likely required for proper
TTSA assembly and with elongated domains at each end that are
required for IpaD functions specific to Shigella spp. (18). Upon
addition of bile salts, IpaD undergoes a conformational change (2,
10), allowing the mobilization of IpaB (62 kDa) to form a ring in a
position distal to IpaD (35). The interaction of IpaB with IpaD
forms the putative plug that controls Shigella type III secretion.
The hydrophobic domain of IpaB then interacts with the host cell
membrane to trigger the secretion of IpaC to complete the conduit
between the bacterium and the host (12). The presence and proper
tip localization of IpaB, IpaC, and IpaD are required for invasion
of epithelial cells. Several studies have reported the presence of
antibodies against Ipa proteins in serum from infected individuals
(5), in subjects immunized with live attenuated organisms during
clinical trials (44, 45), and following vaccination in animal models
(30, 49). The conserved nature of IpaB and IpaD among the shi-
gellae and their critical role in pathogenesis make them ideal tar-
gets for vaccine development. An Ipa-based vaccine would pro-
vide broader coverage across multiple serotypes. It would also
simplify vaccine production and formulation.
We examined the immunogenicity of the Shigella IpaB and
IpaD proteins, administered alone or together, in the presence of a
double mutant heat-labile toxin (dmLT) from enterotoxigenic
Escherichia coli, used as a mucosal adjuvant, in a mouse model of
intranasal immunization. The Shigella proteins were purified us-
ing improved methods and were subjected to stability and confor-
mational analysis. Protective efficacy was determined against le-
thal pulmonary infection with S. flexneri and S. sonnei. We provide
the first demonstration that IpaB and IpaD are promising target
antigens for a cross-protective Shigella vaccine.
MATERIALS AND METHODS
Protein purification materials. Plasmids and competent Escherichia coli
cells were obtained from Novagen (Madison, WI). Metal affinity columns,
Q Sephadex, Butyl Sepharose, and HiLoad 16/60 Superdex 200 prepara-
tive grade columns were obtained from GE Healthcare (Piscataway, NJ).
n-Octyl-polyoxyethylene (OPOE) was obtained from Alexis Biochemicals
(Lausen, Switzerland). All other chemicals were reagent grade.
Protein purification. The E. coli double mutant heat-labile toxin
[LT(R192G/L211A) or dmLT] adjuvant was purified by galactose affinity
chromatography as described previously (33). Recombinant IpaD was
purified as previously described (14). Briefly, BL21(DE3) E. coli contain-
ing the plasmid D/pET15b was grown for 3 h to mid-log phase and
induced by isopropyl--D-thiogalactopyranoside (IPTG) to overexpress
His-tagged IpaD. The bacteria were collected and lysed, and the His-
tagged IpaD was purified from the cytoplasmic fraction via standard im-
mobilized metal affinity column (IMAC) chromatography. Peak fractions
were combined and subjected to a subsequent Q Sephadex anion-
exchange chromatography step. Recombinant IpaB was purified by a
modification of Birket et al. (3). Briefly, ipaB was subcloned into pET15b,
while ipgC was subcloned into pACYC-Duet 1. Tuner(DE3) E. coli cells
were cotransformed with these plasmids. This modification allowed the
purification of the His-tagged IpaB/IpgC complex and the subsequent
removal of the nontagged IpgC. As with IpaD, the bacteria were grown to
mid-log phase and induced with IPTG to overexpress protein, and His-
tagged IpaB/IpgC was purified from the clarified cytoplasmic fraction via
IMAC chromatography. Peak fractions were collected and subjected to
hydrophobic interaction chromatography using a Butyl Sepharose high-
performance column with a linear gradient from 1 M ammonium sulfate
in 50 mM sodium phosphate (pH 7.0) to 50 mM sodium phosphate. For
preparation of His-tagged IpaB, the IMAC-bound protein complex was
incubated in the presence of 1% OPOE. The chaperone was removed in
the flowthrough and in subsequent wash steps. His-tagged IpaB was
eluted in the presence of OPOE to maintain the protein in a soluble form.
His-tagged IpaB was then further purified using size-exclusion chroma-
tography with a HiLoad 16/60 Superdex 200 prep grade column. All pro-
teins were concentrated by ultrafiltration and dialyzed into phosphate-
buffered saline (PBS) (pH 7.2). Protein concentrations were determined
via the absorbance at 280 nm (A280) using extinction coefficients based on
the amino acid composition of each protein (28).
Far-UV circular dichroism (CD) spectra were collected using a Jasco
J815 spectropolarimeter equipped with a Peltier temperature controller
(Jasco Inc., Easton, MD). Spectra were acquired using a cuvette with a
0.1-cm path length at 10°C. A resolution of 1.0 nm and a scanning speed of
50 nm/min with a 2-s data integration time were employed. The spectra
presented are averages of three consecutive measurements. The thermal
unfolding of the proteins was followed by a monitoring of the ellipticity at
222 nm over a temperature range of 10 to 90°C, with a resolution of 2.5°C
and a heating rate of 15°C/h. The protein concentration was 0.5 mg/ml for
IpaD and 0.3 mg/ml for IpaB and IpaB/IpgC. CD signals were converted
to mean residue molar ellipticities ([]R), and the thermal transitions
were analyzed using the Jasco spectral manager and Microcal Origin 6.0
software (25).
Challenge organisms. S. flexneri 2a 2457T and S. sonnei 53G inocula
for challenge were prepared as previously described (29). Briefly, the
strains were grown on tryptic soy agar (TSA) with Congo red (final con-
centration, 0.02%); a total of 20 to 25 colonies were picked and grown in
a volume of 125 ml Luria-Bertani (LB) broth (Athena Environmental
Sciences, Baltimore, MD) with agitation for 3 to 4 h at 37°C or until an
A600 of 0.8 to 1.3 was achieved. Cultures were centrifuged, and bacterial
pellets were resuspended in phosphate-buffered saline (PBS). The num-
bers of CFU of each challenge dose were determined by plating serial
dilutions of the culture on Congo red agar plates. The 50% mouse lethal
doses (MLD50) for the challenge strains were calculated by the method of
Reed and Muench and determined to be 5.4  106 CFU for S. flexneri
and 1.2  107 CFU for S. sonnei.
Mice, immunizations, and challenge procedures. Female BALB/c
mice (8 to 10 weeks old) (Charles River Laboratories, Wilmington, MA)
were immunized intranasally (i.n.) on days 0, 14, and 28 with IpaB (2.5
g), IpaB complexed with IpgC (3.25 g; equivalent to 0.75 g IpgC and
2.5 g IpaB), or IpaD (10 g). The proteins were administered alone or
together, admixed with 2.5 g of the E. coli dmLT adjuvant. Control
groups received 2.5 g of dmLT or PBS. Immunization was performed
under isoflurane anesthesia (Abbott Laboratories, North Chicago, IL) dis-
pensed through a precision vaporizer. The inoculum volume was 25 l,
and it was administered by means of a pipette and tip, delivering half of the
volume in each nare. Animals were allowed to completely recover before
they were returned to their cages, and they were monitored daily after
immunization. On day 56 after primary immunization, mice were chal-
lenged with virulent Shigella strains via the nasal route to induce a pulmo-
nary infection, as previously described (29, 50). Two lethal dosage levels
each were used for both S. flexneri (6  107 and 1.3  108 CFU, corre-
sponding to 11 and 24 MLD50, respectively) and S. sonnei (1.1  108 and
2  108 CFU, corresponding to 5 and 9 MLD50, respectively). The chal-
lenge inoculum was given in a volume of 30 l PBS. Mice were monitored
daily for 14 days after the challenge, and their health status, daily weight,
and survival were recorded. Mice were euthanized if they reached the
moribund state or lost more than 20% of their initial body weight and did
not recover within 48 h. Animal studies and procedures were approved
by the University of Maryland Institutional Animal Care and Use Com-
mittee.
Measurement of antibodies. Serum IgG antibodies to IpaB, IpaD, and
dmLT were measured by an enzyme-linked immunosorbent assay
(ELISA) (39, 40). Briefly, Immulon II ELISA plates (Thermo Scientific,
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Waltham, MA) were coated with IpaB (0.1 g/ml), IpaD (1 g/ml), or
dmLT (1 g/ml) diluted in PBS for 3 h at 37°C. Plates were washed with
PBS Tween (PBST) and blocked overnight with PBS containing 10% dry
milk (Nestle, Solon, OH). Serum samples were added in serial dilutions in
PBST with 10% dry milk and incubated for 1 h at 37°C. Antibodies were
detected with horseradish peroxidase (HRP)-labeled goat anti-mouse IgG
followed by 3,3=,5,5=-tetramethylbenzidine (TMB) substrate (KPL, Gaith-
ersburg, MD). The reaction was stopped by adding 1 M H3PO4. Plates
were read using an Ascent microplate reader (Thermo Scientific, Wal-
tham, MA). Titers were calculated by the interpolation of absorbance
values of experimental samples in the regression curve of a calibrated
positive control; they are reported in ELISA units (EU) per ml and corre-
spond to the inverse of the serum dilution that produces an A450 of 0.2
above the blank. For measurement of stool antibodies, 5 to 6 fecal pellets
from individual animals were weighted and resuspended in PBS contain-
ing 0.2% sodium azide (Sigma-Aldrich, St. Louis, MO) to a final concen-
tration of 10% (wt/vol). Samples were centrifuged, and supernatants were
stored at 20°C with 1 mM phenylmethylsulfonyl fluoride (PMSF)
(Sigma-Aldrich). IgA antibodies to IpaB, IpaD, and dmLT were measured
in stool supernatants by ELISA as described above, using HRP-labeled
goat anti-mouse IgA as the secondary antibody (Southern Biotech, Bir-
mingham, AL).
Antibody-secreting cells (ASC). The frequency of IgG- and IgA-
secreting cells was measured by an enzyme-linked immunosorbent spot
assay (ELISpot) as previously described (39, 40), with modifications.
Spleen, bone marrow, and nasal mucosa-associated lymphoid tissue
(NALT) were collected on days 39 and 56 after immunization, and single-
cell suspensions were prepared. Cells were incubated overnight in Immu-
lon II flat-bottom plates (Thermo Scientific) previously coated with 5
g/ml IpaB or IpaD; PBS-coated wells were used as negative controls.
HRP-labeled goat anti-mouse IgG (KPL) and IgA (Southern Biotech)
were added in the agarose overlay. True Blue (KPL) was used as the sub-
strate. For all ELISpot measurements, spots were counted using a stereo-
microscope and results were expressed as the mean number of spot-
forming cells (SFC) per 106 cells from quadruplicate wells.
IFN- secretion. The frequencies of gamma interferon (IFN-)-
secreting T cells were measured as previously described (39). Spleens were
collected on day 56 following primary immunization, and single-cell sus-
pensions were prepared. Cells (in quadruplicate wells) were incubated
with IpaB or IpaD (10 g/ml) in plates previously coated with anti-IFN-
capture antibody (IFN- ELISpot kit; BD Biosciences, San Diego, CA) for
48 h at 37°C and 5% CO2. IFN- production was detected using a biotin-
ylated anti-IFN- antibody followed by streptavidin-HRP. 3-Amino-9-
ethylcarbazole was used as a peroxidase substrate (Calbiochem, San Di-
ego, CA). Numbers of SFC were calculated and reported as described
above.
Statistical methods. All graphics and statistical analyses were gener-
ated using GraphPad Prism 5. The data distribution was first examined
using the D’Agostino and Pearson normality test. One-way analyses of
variance (ANOVAs) and Tukey’s tests were used for subsequent group
comparisons. Survival curves were plotted in Kaplan-Meier curves; treat-
ments were compared using a log rank test. A P value of 0.05 was con-
sidered significant in all analyses.
RESULTS
Purification of recombinant Shigella IpaB and IpaD. Purifica-
tion of recombinant IpaD and IpaB was performed by modified
previous methods (3, 14). In addition to the standard IMAC pu-
rification, contaminating proteins were removed from the His-
tagged IpaD via anion-exchange chromatography (Fig. 1). The
association of IpaB with its cognate chaperone, IpgC, is required
for IpaB stability in the Shigella cytoplasm (32). Thus, we previ-
ously purified the overexpressed IpaB/IpgC complex via a His tag
genetically fused to the N terminus of IpgC (3). To more effi-
ciently capture IpaB, the plasmid constructs were modified to fuse
the His tag to the N terminus of IpaB, leaving the IpgC untagged.
After standard IMAC purification, the complex was further puri-
fied via hydrophobic interaction chromatography (Fig. 1). When
His-tagged IpaB alone was required, the His-tagged IpaB/IpgC
complex bound to the IMAC resin was incubated with 1% OPOE.
IpgC was washed away, and the His-tagged IpaB was eluted with
buffer containing OPOE. His-tagged IpaB was further purified by
size-exclusion chromatography (Fig. 1).
Far-UV CD spectroscopy was employed to assess the second-
ary structure of the purified proteins. These spectra are routinely
collected to ensure that the purification process has resulted in
proteins maintaining their proper conformation. Thus, CD spec-
troscopy was used to demonstrate that the proteins were unaf-
fected by the additional purification steps (3, 13). Indeed, the
spectra for IpaD, IpaB, and the IpaB/IpgC complex exhibit the
typical -helical minima at 208 and 222 nm (Fig. 2A). While ad-
ditional purification steps have been added to remove contami-
nants, these spectra illustrate that the contaminants have not con-
tributed significantly to previous measurements (3, 14). To assess
the stability of the purified recombinant proteins, thermal unfold-
ing curves were collected. As previously reported (13), IpaD ex-
hibited an initial transition at 60°C and a second transition at 80°C
in which the protein completely unfolds and precipitates (Fig. 2B).
When the IpaB and IpaB/IpgC thermal unfolding curves were
obtained, only one transition was seen, regardless of the presence
of the chaperone (Fig. 2B). Although preliminary results have in-
dicated that IpaB forms a multimeric complex, the IpgC still acts
to stabilize IpaB, a result which is demonstrated by the increase in
the thermal unfolding from 60°C for IpaB to 70°C for IpaB/IpgC.
To determine the initial stability of the proteins under standard
storage conditions, IpaD, IpaB, and IpaB/IpgC in PBS were stored
at 4°C or 80°C and assessed for degradation weekly over a
3-month period using SDS-PAGE. IpaD remained stable for up to
3 months regardless of temperature (data not shown). Both IpaB
and IpaB/IpgC were stable for 3 months at 80°C. In contrast,
IpaB and IpaB/IpgC were stable for only 3 and 4 weeks, respec-
tively, at 4°C. In light of the thermal stability described above, it
was surprising that the IpaB/IpgC complex degraded 25% faster
than IpaB alone at 4°C, albeit only by 1 week. While these data
FIG 1 SDS-PAGE of purified recombinant proteins. IpaD (lane 1), IpaB (lane
2), and IpaB/IpgC (lane 3) (5 g each) were subjected to SDS-PAGE and
subsequently stained with Coomassie blue R-250. Molecular mass markers (in
kDa) are on the left.
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appear contradictory to the data from the thermal unfolding,
where the complex was more stable, it is likely that the binding of
IpgC to IpaB results in unstructured regions that are unique to the
complex and available for proteolytic cleavage. A complete bio-
physical characterization of IpaB and the complex is ongoing
(S. P. Choudhari, R. Krammer, C. R. Middaugh, and W. L. Pick-
ing, unpublished data).
Mucosal immunization with IpaB/IpaD proteins elicits
strong antibody responses. The kinetics of serum IgG responses
against Shigella IpaB and IpaD and the E. coli dmLT adjuvant are
shown in Fig. 3. Mice immunized i.n. with the Ipa proteins alone
(i.e., IpaB, the IpaB/IpgC complex, or IpaD) or combined (i.e.,
IpaB and IpaD [IpaBIpaD] or IpaB/IpgCIpaD) in the pres-
ence of dmLT developed robust antigen-specific antibody re-
sponses. Serum IgG antibodies to IpaB were detected soon after
immunization (2 weeks after the first vaccine dose), whereas an-
tibodies against IpaD appeared later (2 weeks after the second
immunization). For both IpaB and IpaD, serum IgG levels
reached a plateau after the third immunization. No differences
were seen in the serum IgG responses to either of the vaccine
antigens among the different groups regardless of whether the Ipa
proteins, admixed with dmLT, were administered alone (IpaB,
IpaB/IpgC, or IpaD) or together (IpaBIpaD or IpaB/
IpgCIpaD). Interestingly, despite the fact that the amount of
IpaB used for immunization was a fraction (1:4) of the amount of
IpaD (2.5 g versus 10 g), the antibody responses to IpaB con-
sistently surpassed the responses induced by IpaD by at least 1 log
at all time points examined (P  0.05) and in all the experiments
performed. The amounts of IpaB and IpaD used for immuniza-
tion were established in preliminary dosing experiments in which
increasing quantities of either protein (2.5 g to 20 g) were ad-
ministered with dmLT. Increasing amounts of dmLT were also
tested. We selected the 1:4 dose ratio (2.5 g of IpaB and 10 g of
IpaD) and 2.5 g of dmLT for subsequent experiments because,
when combined in such proportions, the proteins were well toler-
ated and reached the highest responses within the variables tested.
FIG 2 CD spectroscopy of recombinant proteins. (A) Far-UV spectra of re-
combinant proteins were recorded at 10°C in 10 mM phosphate-citrate buffer
at pH 7.2. (B) Temperature dependence of the molar ellipticity at 222 nm of
recombinant proteins was monitored from 10°C to 90°C at 2.5°C intervals at a
rate of 15°C/h. Error bars have been omitted for clarity; uncertainty was less
than 5% (n  3).
FIG 3 Serum antibody responses to IpaB, IpaD, and dmLT. Mice were im-
munized on days 0, 14, and 28 (arrows) with IpaB, IpaB/IpgC, and/or IpaD
admixed with dmLT, as described in Materials and Methods. Serum IgG anti-
bodies specific for IpaB (A), IpaD (B), and dmLT (C) were measured by ELISA.
Data are the mean titers (EU ml1) and the standard errors (SE) from 10 mice
per group. An asterisk indicates a P value of 0.05 when comparing vaccinated
mice and the PBS controls. (A) No responses were seen in mice that received
IpaD alone or PBS. (B) No responses were seen in mice immunized with IpaB
or IpaB/IpgC or PBS. (C) No responses were detected in the PBS control.
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The IpaB/IpgC complex was not included in dose-finding studies
but was used in the same amount as IpaB.
Very strong serum IgG responses were also produced against
the adjuvant E. coli dmLT. Elevated titers were detected 2 weeks
after vaccination and reached a plateau 2 weeks after the second
dose. No differences were seen in titers among the different treat-
ment groups. The dmLT-specific IgG responses were consistently
high in all the experiments performed.
Ipa-specific IgA- and IgG-secreting cells in systemic tissues.
In addition to serum antibodies, we measured the frequency of
vaccine-induced ASC in spleen and bone marrow. These cells rep-
resent pools of long-lived plasma cells and memory cells, respec-
tively, which have the capacity to maintain circulating antibody
levels. IgG and IgA ASC specific for IpaB and IpaD were detected
in the spleens of vaccinated mice 1 month after the last immuni-
zation (Fig. 4A). Mice that received IpaB or the IpaB/IpgC com-
plex, either alone or coadministered with IpaD, developed high
frequencies of IpaB-specific IgA- and IgG-secreting cells (between
200 and 300 SFC per 106 cells). ASC responses against IpaD were
also detected, but the frequency was lower than that of ASC re-
sponses against IpaB (P  0.05). While responses to IpaB included
both IgG- and IgA-secreting cells, the ASC responses to IpaD con-
sisted primarily of IgG-secreting cells (10 to 150 SFC per 106 cells).
Similar ASC response profiles and levels were seen in the spleen on
day 39 after immunization (data not shown).
Similarly, vaccine-induced IgG- and IgA-secreting cells against
IpaB were found in the bone marrow of vaccinated mice (Fig. 4B).
ASC responses were also produced against IpaD, albeit at signifi-
cantly lower levels (P  0.05). The frequencies of ASC responses
against both IpaB and IpaD in the bone marrow were lower (30
SFC per 106 cells) than the frequencies measured in the spleen (40
to 300 per 106 cells). In bone marrow, we did not see the preva-
lence of IpaD-specific IgG ASC that was found in the spleen, pos-
sibly because all responses to IpaD were markedly low. When
comparing ASC responses among the different groups and treat-
ments, the ASC responses to IpaB and IpaD were similar regard-
less of whether IpaB was complexed with IpgC or whether IpaB
and IpaD were given alone or together. No ASC responses to IpaB
and IpaD were detected in mice that received dmLT alone or in
mice in the PBS controls.
Stool IgA and nasal ASC responses following immunization
with IpaB and IpaD. To demonstrate the induction of antibodies
in the gastrointestinal mucosas, which represent the first line of
adaptive immune defense against enteric pathogens, we measured
IgA responses to IpaB and IpaD in stool supernatants from vacci-
nated and control mice (Fig. 5). The kinetics of IpaB-specific IgA
production were similar among the different groups. Unlike the
serum IgG responses, which appeared relatively soon after vacci-
nation, the fecal IgA responses were somewhat delayed. IgA titers
to IpaB were first seen after the second immunization; IgA re-
sponses to IpaD appeared after the third immunization, indicat-
ing that an additional vaccine dose was required to raise detectable
mucosal antibodies to the levels found in the serum. As with the
serological responses, the intestinal IgA responses to IpaD were
significantly lower than those against IpaB. For both antigens, IgA
titers reached a plateau 2 weeks after the third immunization. No
differences were seen in the IpaB stool IgA titers among the groups
that received IpaB or IpaB/IpgC alone or IpaB or IpaB/IpgC com-
bined with IpaD. A trend of higher IpaD IgA responses was seen in
mice immunized with IpaD alone, although it did not reach statistical
significance. Very high levels of stool IgA, which were similar in all
treatment groups, were produced in response to the dmLT; responses
were detected after the first immunization and had already reached
maximum levels after the second dose of vaccine.
IgG and IgA ASC specific for IpaB and IpaD were detected in
the nasal tissue on day 56 after immunization (Fig. 6). The fre-
quencies of IpaB-specific ASC were again higher than those mea-
sured against IpaD (P  0.05). No significant differences were
seen in the numbers of ASC against IpaB and IpaD among the
different groups, regardless of whether IpaB or IpaB/IpgC was
used or whether these proteins were given alone or coadminis-
tered with IpaD.
Intranasal immunization with IpaB and IpaD elicits robust T
cell-mediated immunity. T cells, in addition to antibodies, are
FIG 4 Antibody-secreting cells in spleen and bone marrow. Spleens (A) and
bone marrows (B) were collected on day 56. Single-cell suspensions from 5
mice per group were stimulated in vitro with IpaB or IpaD. IgG and IgA ASC
were measured by ELISpot. Bars represent the mean numbers of ASC per 106
cells and the standard deviations (SDs) from replicate wells. An asterisk indi-
cates a P value of 0.05 when comparing that condition with PBS control
mice.
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believed to contribute to protection against Shigella infection
through the secretion of proinflammatory mediators that will fur-
ther activate innate immune cells and T helper cytokines that will
support antibody production. T cells might also contribute to
clearing the infection by promoting T cytotoxic cell- or NK-
mediated killing of infected cells. The frequency of IFN--
secreting T cells specific for IpaB and IpaD was measured in the
spleens of vaccinated and control mice 1 month after the last im-
munization (Fig. 7). Intranasal immunization with IpaB and IpaD
induced antigen-specific T cells that were able to produce IFN-
when stimulated in vitro. The IFN- responses to IpaB (50 to 150
SFC per 106 cells) were higher than those measured against IpaD
(50 SFC per 106 cells). An interesting finding, which was not
paralleled in the serological analysis, was a trend of a higher mag-
nitude of IFN--secreting T cells in mice immunized with IpaB or
IpaB/IpgC as well as IpaD (P  0.05). This was true for the re-
sponses against both antigens, IpaB and IpaD. The frequencies of
IFN--producing cells were consistently lower in groups that re-
ceived IpaB, IpaB/IpgC, or IpaD alone. No responses were de-
tected in negative-control groups that received dmLT and PBS.
Protection against S. flexneri and S. sonnei lethal pulmonary
challenge. To determine the protective efficacy of IpaB and IpaD,
vaccinated and control mice were subjected to a lethal pulmonary
dose of homologous S. flexneri 2a or heterologous S. sonnei (Fig.
8). Two lethal dosage levels for each species were used to perform
a more stringent protection analysis: 0.6  108 and 1.3  108 CFU
of S. flexneri, corresponding to 11 and 24 MLD50, respectively, and
1.1  108 and 2  108 CFU of S. sonnei, corresponding to 5 and 9
MLD50, respectively. Protective efficacy of the Ipa proteins when
using the lower challenge dose was between 90 and 100% against
S. flexneri (Fig. 8A) and between 60 and 80% against S. sonnei. The
highest level of protection was seen in mice immunized with IpaB
or IpaB/IpgC. When the challenge dose was doubled, the homol-
ogous and heterologous protection achieved in the vaccinated
groups was somewhat lower but still significant compared with
that of the unvaccinated controls (Fig. 8B). Immunization with
FIG 5 Fecal IgA responses to IpaB, IpaD, and dmLT. Mice were immunized
on days 0, 14, and 28 (arrows). IgA specific for IpaB (A), IpaD (B), and dmLT
(C) was measured by ELISA in stool supernatants. Data are the mean titers (EU
ml1) and the SE from 10 mice per group, except for at day 56, when there were
5 mice in each group. An asterisk indicates a P value of 0.05 when comparing
that condition with PBS control mice. (A) No responses were seen in mice that
received IpaD alone or PBS. (B) No responses were seen in mice immunized
with IpaB or IpaB/IpgC or PBS. (C) No responses were detected in the PBS
control.
FIG 6 Antibody-secreting cells in nasal tissue. Nasal mucosa-associated lym-
phocyte tissue was collected on day 56, and single-cell suspensions were pre-
pared from 5 mice per group. IgG and IgA ASC-specific IpaB and IpaD were
measured by ELISpot. Bars represent the means and SDs per 106 cells from
replicate wells. An asterisk indicates a P value of 0.05 when comparing that
condition with PBS control mice.
FIG 7 IFN--secreting cells. Spleens were collected on day 56 from 5 mice per
group. Single-cell suspensions were prepared and stimulated with 5 g/ml
IpaB or IpaD for 48 h. Results are the numbers of IFN- SFC per 106 cells and
SDs from quadruple wells. An asterisk indicates a P value of 0.05 when
comparing that condition with mice that received PBS.
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IpaB afforded 50% protection against S. flexneri, whereas 30%
protection was attained when IpaB was coadministered with IpaD
(Fig. 8B). Protection against the higher challenge dose of S. sonnei
was 50% in mice immunized with IpaB and 45% in mice that
received IpaB coadministered with IpaD. The addition of IpaD
did not increase the survival rate in any of the challenges, regard-
less of the challenge dose. Nevertheless, a significant proportion of
mice immunized with IpaD alone (70 to 90%) were protected
when challenged with the lower lethal infectious doses, although
this level of protection decreased drastically (20 to 30%) when
they were exposed to a higher number of organisms of either
strain. A summary of the protective efficacy values and the statis-
tical significance when comparing the vaccinated and control
groups is shown in Table 1.
DISCUSSION
Despite intense efforts, the development of an effective vaccine
against Shigella remains a daunting task. One of the main chal-
lenges in achieving an effective prophylactic tool against this
pathogen is the need to protect against multiple serotype strains.
FIG 8 Protection against Shigella spp. in a lethal pulmonary challenge. Mice were challenged on day 56 after the first immunization. Two dosage levels were used
for each strain, including 6  107 CFU of S. flexneri, corresponding to 11 MLD50, and 1.1  108 CFU of S. sonnei (5 MLD50) (A) and 1.3  108 CFU of S.
flexneri, corresponding to 24 MLD50, and 2  108 CFU of S. sonnei (9 MLD50) (B). Data are the percentages of survival for 10 mice in each group.




Protective efficacy (%) of each vaccinea
IpaBdmLT IpaDdmLT IpaBIpaDdmLT IpgCdmLT IpgCIpaDdmLT dmLT PBS
S. flexneri 1.2  108 50* 20 30* ND ND 0 0
S. sonnei 2.0  108 55.5* 30* 50* ND ND 0 0
S. flexneri 6.0  107 100* 88* 90* 100* 90* 0 0
S. sonnei 1.1  108 80* 70* 80* 80* 60* 0 0
a ND, not determined. Asterisks indicate a P value of 0.05 when comparing that condition with the group receiving dmLT (log rank test).
Martinez-Becerra et al.
1228 iai.asm.org Infection and Immunity
Antibodies to LPS have been associated with serotype-specific
protection against shigellosis (8, 9, 47), yet the existence of struc-
turally and antigenically different LPS molecules limits the appli-
cability of an LPS-containing vaccine.
Our approach to develop a safe and effective vaccine to prevent
this disease involves the use of conserved proteins that could pro-
vide broad protection against multiple serotypes. Among poten-
tial cross-protective antigens, we focused our attention on the
exposed proteins of the TTSA. These proteins are encoded as part
of the mxi-spa operon located on the large virulence plasmid that
is present in all Shigella spp. Thus, in addition to being nearly
identical among pathogenic Shigella strains, they mediate critical
steps of bacterial pathogenesis. IpaB and IpaD were selected be-
cause of their significant roles during TTSS-mediated events that
lead to bacterial invasion of epithelial cells. IpaD localizes to the
needle tip, where it controls further assembly of the TTSA as well
as TTSS effector secretion. IpaB is subsequently recruited to the
tip of the needle, where it interacts with host membranes to initi-
ate formation of the translocon/pore complex. Immunological
effector mechanisms (i.e., antibodies) that can interfere with their
function in vivo may potentially prevent bacterial infection, mak-
ing them very attractive vaccine target antigens.
We examined the immunogenicity of IpaB and IpaD (alone or
combined) in a mouse intranasal immunization model using the
E. coli dmLT as an adjuvant and demonstrated that both proteins
were able to induce robust serum and mucosal antibody levels and
elevated frequencies of antibody-secreting cells in mucosal and
systemic tissues. They also induced strong antigen-specific cell-
mediated immunity responses, evidenced by the presence of IFN-
-secreting T cells. Most important, very high levels of protection
(80 to 100%) were achieved against a homologous strain and a
heterologous strain using a lethal pulmonary challenge model. In
the absence of dmLT, modest antibody responses to IpaB and
IpaD were induced, but no protection was achieved (S. Heine,
S. H., G. Fujii, W. L. Picking, and M. F. Pasetti, unpublished data).
The dmLT molecule is a derivative of the heat-labile enterotoxin
of E. coli with two attenuating mutations in the enzymatically
active A subunit (R192G/L211A). These mutations effectively re-
duce enterotoxicity without impacting the adjuvant properties of
the molecule (33). It was chosen as an adjuvant for our studies
because it has been shown to enhance the production of vaccine-
specific humoral and cell-mediated immune responses in both the
systemic and mucosal compartments when it is included as part of
a vaccine formulation (33).
IpaB was consistently and across measurements the more im-
munogenic of the two proteins. Both serum IgG and stool IgA
responses to IpaB appeared faster and achieved a higher magni-
tude than the responses induced by IpaD. This superior immuno-
genicity was also seen at the T cell response level. The coadminis-
tration of proteins had no effect on their individual serological
responses, although it appeared to have an impact on the T cell
responses, as discussed below. The presence of high frequencies of
IpaB/IpaD-specific ASC in the spleen indicates the capacity of the
vaccine to induce a large pool of functional plasma cells, which are
the source of systemic antibodies. The demonstration of antigen-
specific ASC in the bone marrow indicates the existence of B
memory cells, which can reactivate upon a subsequent antigen
encounter to mount a rapid and strong anamnestic response and
thus contribute to long-term protection.
The abilities to generate mucosal antigen-specific ASC and to
produce intestinal secretory IgA (sIgA) are also important features
of our IpaB/IpaD-based vaccine, as these immunological effectors
would be necessary to prevent mucosal enteric infection in hu-
mans. Although the mechanisms of protection against Shigella
have not been elucidated, mucosal immune defenses are sought,
as they block pathogens in the intestinal lumen, preventing patho-
genic attachment and infection of epithelial cells. Ipa-specific sIgA
antibodies are expected to neutralize TTSS interactions at the mu-
cosal epithelial barrier, thereby preventing bacterial invasion of
host cells. IgG antibodies might also contribute to protection
when infection has occurred, facilitating opsonophagocytic killing
by polymorphonuclear neutrophils and macrophages (42).
In addition to producing antibodies, both IpaB and IpaD in-
duced high frequencies of IFN--secreting T cells, demonstrating
the presence of robust cell-mediated immunity. Production of
IFN- is required for the protection of mice against Shigella pul-
monary infection (26). Likewise, T cell-mediated immunity is
thought to be necessary for the protection of humans against shig-
ellosis. IFN--activated macrophages abrogate bacterial growth,
whereas in the absence of IFN-, Shigella replicates intracellularly
and further disseminates, a result which suggests an IFN--
mediated mechanism for controlling infection (52). Production
of IFN- in response to IpaB has been demonstrated using periph-
eral blood mononuclear cells (PBMCs) from infected individuals
(41) or from subjects that received live attenuated vaccine organ-
isms (23).
In our studies, the production of IFN- appeared to be in-
creased when IpaB/IpaD were administered together compared to
that of the proteins given alone, suggesting a synergistic or more
effective activation of antigen-presenting cells or Th1 lympho-
cytes. Interestingly, the increased responses appeared to be limited
to T cells, as they were not seen in the antibody or ASC measure-
ments. This effect was not due to cross-reactivity or contamina-
tion, as cells from mice immunized with IpaB did not respond
against IpaD and vice versa.
Although IpaB degrades when expressed in the E. coli cyto-
plasm, it can be stably coexpressed and purified with its cognate
chaperone, IpgC. The complex can then be separated by the addi-
tion of the detergent OPOE, which results in stable, multimeric
IpaB. While IpaB would be the obvious antigen, separation from
IpgC requires an additional purification step and the use of a de-
tergent not generally recognized as safe (GRAS), OPOE, which is
currently the only detergent found to efficiently separate the com-
plex. This lengthens the purification process and increases pro-
duction costs. Thus, the question emerged as to whether IpaB/
IpgC is equally as immunogenic as IpaB and can serve as a vaccine
antigen. We found no significant differences between IpaB and
IpaB/IpgC in any of the responses measured. This finding may
facilitate the production of a vaccine with a more simple produc-
tion process and reduced costs.
Mice immunized with IpaB/IpaD were protected against Shi-
gella lethal infection in a pulmonary challenge. Heterologous pro-
tection was also observed using Shigella sonnei. Protection in the
lower-dose challenge was significant for all combinations of Ipa
proteins tested. In agreement with the lower immune responses,
immunization with IpaD afforded lower protection than immu-
nization with IpaB. Protection conferred by IpaB/IpgC was com-
parable to that induced by purified IpaB.
Contrary to what we expected, the combination IpaB/IpaD did
not result in increased protection in any of the challenge condi-
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tions. We believe, however, that it is still advantageous to maintain
both antigens in a future vaccine candidate since IFN- responses
seemed to be improved, a result which might be important to
enhance protection in humans.
Another vaccine candidate that contains Shigella Ipa proteins is
the “Invasin-LPS complex,” or Invaplex. This vaccine consists of a
mixture of IpaB, IpaC, and LPS (and possibly other antigens)
present in water extracts from intact Shigella species (49). Two
chromatographic fractions, designated Invaplex 24 and 50, were
immunogenic and protective against homologous virulent strains
in mice and guinea pigs (34). The S. flexneri 2a Invaplex 50 vaccine
was safe and immunogenic when administered intranasally to hu-
man volunteers in phase 1 clinical studies (43, 48). However, this
vaccine failed to protect subjects from a subsequent oral challenge
with virulent S. flexneri 2a 2457TC. Harro et al, Shigella flexneri 2a
Invaplex 50 intranasal vaccine phase 2b challenge study, presented
at the 5th Int. Conf. Vaccines Enteric Dis., 9 to 11 September 2009,
Malaga, Spain. Unlike the Invaplex, our vaccine contains known
quantities of highly purified IpaB, along with IpaD, and it does not
contain LPS.
Although antibodies to LPS are known to mediate protection
against shigellosis, our study provides the first evidence that pro-
tective immunity can be induced by the IpaB/IpaD vaccine com-
bination and in the absence of LPS. A protein-based, LPS-free
vaccine would be safer and more amenable for use in infants,
young children, and immune-compromised individuals. The
demonstration of cross-protective immunity using purified TTSA
proteins is also novel and has broader implications, as the TTSA
tip proteins from other Gram-negative enteric pathogens may
prove to be protective antigens as well. Through the use of efficient
antigen delivery systems, TTSA-based vaccines may potentially be
administered to humans to induce mucosal immunity.
In sum, a subunit-based IpaB/IpaD vaccine may be an effec-
tive, broadly protective vaccine for prevention of shigellosis.
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